Cefuroxime Granules

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococci, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor. The mechanism of action is the same as other cephalosporins, which is to inhibit the synthesis of bacterial cell walls.

The main ingredient of this product is cefradine, and its chemical name is (6R,7R)-7[(R)-2-amino-2-(1,4-cyclohexenyl)acetylamino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

This product is a granule with added flavoring agent.

It is suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis, pneumonia and other respiratory tract infections, urogenital tract infections and skin and soft tissue infections caused by sensitive bacteria. This product is an oral preparation and should not be used for severe infections.

Common oral dosage for adults: 0.25-0.5g once, once every 6 hours. For patients with more serious infections, the dosage can be increased to 1g once, but the total daily dosage should not exceed 4g. Common oral dosage for children: 6.25-12.5mg/kg once, once every 6 hours.

The adverse reactions of this product are mild and the incidence is low, about 6%. Gastrointestinal reactions such as nausea, vomiting, diarrhea, and upper abdominal discomfort are more common. The incidence of drug rash is about 1% to 3%. Pseudomembranous colitis, eosinophilia, positive reaction to direct Coombs test, peripheral blood leukocytopenia and neutrophil granulocytes, dizziness, chest tightness, candidal vaginitis and allergic reactions are seen in individual patients. A small number of patients may experience temporary increases in blood urea nitrogen, serum aminotransferase, and serum alkaline phosphatase.

This product and other cephalosporins are contraindicated.

Precautions for children: Not clear yet. Precautions for pregnancy and lactation: Because this product can enter the fetal blood circulation through the blood-placenta barrier, pregnant women need to have specific indications for medication. This product can also enter breast milk in small amounts. Although there are no reports of problems with the use of cephalosporins in lactating women, it is still necessary to weigh the pros and cons before using it. Precautions for the elderly: Elderly patients are often accompanied by impaired renal function, and the dose should be appropriately reduced or the dosing interval should be extended.

1. Cephalosporins can delay the excretion of phenytoin sodium in the renal tubules. 2. Phenylbutazone combined with cephalosporin antibiotics can increase renal toxicity. 3. Combined with strong diuretics can increase renal toxicity. 4. Combined with mecillinam, it has a synergistic effect on gram-negative bacteria such as Escherichia coli and Salmonella. 5. Probenecid can delay the excretion of this product.

Seal tightly and store in a cool, dark place.

0.125g

24 months

Jinri Pharmaceutical (China) Co., Ltd.

• Founded in:

  1991-07-05

• Address:

  Jinri Industrial Village, Jinri Road, Tongan District, Xiamen

• Tax NO.:

  91350200612009145K

• Registered Funds:

  225.5 million yuan

• Website:

  Log in to view

• Email:

  Log in to view